BDBM601951 6'-hydroxy-2'-((4-(4- methylpiperazine-1- carbonyl)phenyl)amino)-6',7'- dihydro-8'H-spiro[cyclohexane-1,9'- pyrazino[1',2':1,5]pyrrolo[2,3- d]pyrimidin]-8'-one::US11643416, Compound 53::US20240150369, Compound 53

SMILES CN1CCN(CC1)C(=O)c1ccc(Nc2ncc3cc4C(O)NC(=O)C5(CCCCC5)n4c3n2)cc1

InChI Key InChIKey=VASFNXBXECJRSY-UHFFFAOYSA-N

Data  18 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 18 hits for monomerid = 601951   

TargetCyclin-A2/Cyclin-dependent kinase 2(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM601951(US11643416, Compound 53 | 6'-hydroxy-2'-((4-(4- me...)
Affinity DataIC50: 2nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, CA) to determine their inhibitory effect on these CDKs. The...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/9/2024
Entry Details
Go to US Patent

TargetCyclin-H/Cyclin-dependent kinase 7(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM601951(US11643416, Compound 53 | 6'-hydroxy-2'-((4-(4- me...)
Affinity DataIC50: 615nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, CA) to determine their inhibitory effect on these CDKs. The...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/9/2024
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 5 activator 1(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM601951(US11643416, Compound 53 | 6'-hydroxy-2'-((4-(4- me...)
Affinity DataIC50: 4nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, CA) to determine their inhibitory effect on these CDKs. The...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/9/2024
Entry Details
Go to US Patent

Targetcdk3cyclin-e(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM601951(US11643416, Compound 53 | 6'-hydroxy-2'-((4-(4- me...)
Affinity DataIC50: 10nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, CA) to determine their inhibitory effect on these CDKs. The...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/9/2024
Entry Details
Go to US Patent

TargetCyclin-dependent kinase/G2/mitotic-specific cyclin- 1(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM601951(US11643416, Compound 53 | 6'-hydroxy-2'-((4-(4- me...)
Affinity DataIC50: 27nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, CA) to determine their inhibitory effect on these CDKs. The...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/9/2024
Entry Details
Go to US Patent

TargetCyclin-T1/Cyclin-dependent kinase 9(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM601951(US11643416, Compound 53 | 6'-hydroxy-2'-((4-(4- me...)
Affinity DataIC50: 10nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, CA) to determine their inhibitory effect on these CDKs. The...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/9/2024
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 6/G1/S-specific cyclin-D3(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM601951(US11643416, Compound 53 | 6'-hydroxy-2'-((4-(4- me...)
Affinity DataIC50: 5nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, CA) to determine their inhibitory effect on these CDKs. The...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/9/2024
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM601951(US11643416, Compound 53 | 6'-hydroxy-2'-((4-(4- me...)
Affinity DataIC50: 2nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, CA) to determine their inhibitory effect on these CDKs. The...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/9/2024
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM601951(US11643416, Compound 53 | 6'-hydroxy-2'-((4-(4- me...)
Affinity DataIC50: 4nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, CA) to determine their inhibitory effect on these CDKs. The...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/9/2024
Entry Details
Go to US Patent

TargetCyclin-A2/Cyclin-dependent kinase 2(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM601951(US11643416, Compound 53 | 6'-hydroxy-2'-((4-(4- me...)
Affinity DataIC50: 2nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2023
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 7(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM601951(US11643416, Compound 53 | 6'-hydroxy-2'-((4-(4- me...)
Affinity DataIC50: 615nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2023
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 5 activator 1(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM601951(US11643416, Compound 53 | 6'-hydroxy-2'-((4-(4- me...)
Affinity DataIC50: 4nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2023
Entry Details
Go to US Patent

Targetcdk3cyclin-e(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM601951(US11643416, Compound 53 | 6'-hydroxy-2'-((4-(4- me...)
Affinity DataIC50: 10nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2023
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 1(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM601951(US11643416, Compound 53 | 6'-hydroxy-2'-((4-(4- me...)
Affinity DataIC50: 27nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2023
Entry Details
Go to US Patent

TargetCyclin-T1/Cyclin-dependent kinase 9(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM601951(US11643416, Compound 53 | 6'-hydroxy-2'-((4-(4- me...)
Affinity DataIC50: 10nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2023
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 6/G1/S-specific cyclin-D3(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM601951(US11643416, Compound 53 | 6'-hydroxy-2'-((4-(4- me...)
Affinity DataIC50: 5nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2023
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM601951(US11643416, Compound 53 | 6'-hydroxy-2'-((4-(4- me...)
Affinity DataIC50: 2nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2023
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM601951(US11643416, Compound 53 | 6'-hydroxy-2'-((4-(4- me...)
Affinity DataIC50: 4nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2023
Entry Details
Go to US Patent